PatientsVille.com Logo

Hyperlipidaemia and Zocor

PatientsVille

Hyperlipidaemia Symptoms and Causes

Cholesterol is a waxy, fat-like substance that occurs naturally in all parts of the body. Your body needs some cholesterol to work properly. But if you have too much in your blood, it can combine with other substances in the blood and stick to the walls of your arteries. This is called plaque. Plaque can narrow your arteries or even block them.

There are two main types of cholesterol:

  • HDL stands for high-density lipoproteins. It is called the "good" cholesterol because it carries cholesterol from other parts of your body back to your liver. Your liver then removes the cholesterol from your body.
  • LDL stands for low-density lipoproteins. It is called the "bad" cholesterol because a high LDL level leads to a buildup of cholesterol in your arteries.

High levels of cholesterol in the blood can increase your risk of heart disease. Your cholesterol levels tend to rise as you get older. There are usually no signs or symptoms that you have high blood cholesterol, but it can be detected with a blood test. You are likely to have high cholesterol if members of your family have it, if you are overweight or if you eat a lot of fatty foods.

You can lower your cholesterol by exercising more and eating more fruits and vegetables. You also may need to take medicine to lower your cholesterol.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for hyperlipidaemia

hyperlipidaemia treatment research studies

Zocor clinical trials, surveys and public health registries


Find Drug Side Effect reports



Zocor Side Effects

Rhabdomyolysis (1045)
Myalgia (844)
Blood Creatine Phosphokinase Increased (494)
Asthenia (430)
Muscular Weakness (393)
Renal Failure Acute (366)
Pain In Extremity (328)
Arthralgia (302)
Muscle Spasms (284)
Fatigue (263)
Myopathy (253)
Renal Failure (231)
Pain (228)
Dyspnoea (220)
Myocardial Infarction (202)
Myositis (201)
Nausea (196)
Alanine Aminotransferase Increased (184)
Chest Pain (179)
Dizziness (178)
Fall (128)
Aspartate Aminotransferase Increased (127)
Malaise (122)
Cerebrovascular Accident (120)
Diarrhoea (119)
Headache (104)
Back Pain (101)
Liver Function Test Abnormal (101)
Depression (100)
Abdominal Pain (95)
Gait Disturbance (93)
Blood Creatinine Increased (93)
Anxiety (92)
Abasia (91)
Vomiting (87)
Amnesia (86)
Abdominal Pain Upper (79)
Anaemia (78)
Coronary Artery Disease (76)
Insomnia (75)
Cardiac Failure Congestive (74)
Weight Decreased (73)
Dehydration (72)
Pyrexia (71)
Confusional State (70)
Paraesthesia (70)
Hypertension (69)
Pneumonia (69)
Rash (68)
Cardiac Disorder (67)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Hyperlipidaemia Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia
Conditions: Essential Hypertension;   Hyperlipidemia
Interventions: Drug: Atorvastatin;   Drug: Losartan;   Drug: Placebo;   Drug: HL-040XC
Outcome Measures: Change from baseline to 8 week in SiDBP (Sitting Diastolic Blood Pressure);   Percent change from baseline to 8 week in LDL-Cholesterol;   Percentage of patients reaching treatment goals according to NCEP ATP III Guideline and Blood Pressure Responder according to JNC VII Guideline.
2 Not yet recruiting Efficacy and Safety Study of Dietary Supplements in Chronic Smokers Having Mild to Moderate Hyperlipidemia
Conditions: Chronic Smokers;   Hyperlipidemia
Interventions: Other: Placebo;   Dietary Supplement: BioTurmin (Curcuma longa rhizomes extract);   Dietary Supplement: BioTurmin-WD (Water dispersible curcuminoids);   Dietary Supplement: MaQxan (Tagetes erecta flower extract)
Outcome Measures: Change in urine cotinine and serum oxidative stress marker levels;   Change in serum lipid profile
3 Not yet recruiting Randomized Clinical Trial of RN316 (PF-04950615) inSubjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events.
Condition: Hyperlipidemia
Interventions: Drug: PF-04950615;   Other: Placebo
Outcome Measures: Percent Change from Baseline in fasting LDL-C at week 12.;   Change from baseline in fasting Lipid Parameters at Week 12.;   Change from baseline in fasting Lipid Parameters at Week 24.;   Change from baseline in fasting Lipid Parameters at Week 52.;   Proportion of subjects achieving fasting LDL-C <=100 mg/dL and <=70 mg/dL at week 12.;   Proportion of subjects achieving fasting LDL-C <=100 mg/dL and <=70 mg/dL at week 24.;   Proportion of subjects achieving fasting LDL-C <=100 mg/dL and <=70 mg/dL at week 52.;   Plasma PF-04950615 concentration at week 12.;   Plasma PF-04950615 concentration at week 24.;   Plasma PF-04950615 concentration at week 52.
4 Recruiting Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia
Conditions: Hypertension;   Hyperlipidemia
Interventions: Drug: Telmisartan 80mg;   Drug: Rosuvastatin 20mg;   Drug: Rosuvastatin 10mg;   Drug: Placebo(for Telmisartan 80mg);   Drug: Placebo(for Rosuvastatin 20mg);   Drug: Placebo(for Rosuvastatin 10mg)
Outcome Measures: •Change in seated diastolicblood pressure at 8 weeks compared to the base value;   Change in LDL-Cat 8 weeks compared to the base value (% change);   Change in seateddiastolic blood pressure;   Change in seated systolic blood pressure;   Rate of patients achieving a therapeutic purpose according to JNC VII Guideline [therapeutic purpose for blood pressure: < 140/90 mmHg (however, < 130/80 mmHg for Group III)];   Change in LDL-Cat compared to the base value (% change);   Change in TC, TG, HDL-C and Apolipoprotein B compared to the base value (% change);   Rate of patients achieving a therapeutic purpose according to NCEP ATP III Guideline therapeutic purpose for LDL-C- (Group I: < 160 mg/dL, Group II: < 130 mg/dL, Group III: < 100 mg/dL)
5 Unknown  Jiangzhuo Prescription ,Fenofibrate and Placebo in the Treatment of Hyperlipidemia (Syndrome of Phlegm Obstruction)Clinical Study (JZF)
Conditions: Metabolic Syndromes;   Hyperlipidemia
Intervention:
Outcome Measure:
6 Recruiting Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia
Condition: Hyperlipidemia, Familial Combined
Interventions: Drug: Atorvastatin 20mg;   Drug: Omega-3-acids ethylesters 90 4g;   Other: Placebo(Omega-3-acids ethylesters 90)
Outcome Measures: The mean percent change of Triglyceride(TG);   The mean percent change of Total Cholesterol(TC), LDL-C, HDL-C
7 Recruiting Comparison of the Efficacy and Safety of AtorVastatin mOnotherapy vs. Combination Atorvastatin/Fenofibric Acid
Condition: Mixed Hyperlipidemia
Interventions: Drug: Atorvastatin 10mg, fenofibric acid 135mg;   Drug: atorvastatin 20mg
Outcome Measures: Changes of non-HDL cholesterol;   levelresponse rate of non-HDL cholesterol level < 130mg/dL;   changes of TC,HDL-C,LDL-C,TG,Apo B/A1;   Changes of Glucose, HbA1c, HOMA-IR level;   Changes of hs-CRP, adiponectin, resistin level
8 Unknown  Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of HYPERLIPIDAEMIA in HIV-infected Patients
Conditions: HIV;   Hyperlipidemia;   HIV Infections
Interventions: Drug: ezetimibe;   Drug: fenofibrate;   Drug: pravastatin
Outcome Measure: per cent changes of LDL cholesterol, comparison between the 2 treatment regimens
9 Unknown  Cardiovascular Effects of Salvia Miltiorrhiza Extract (Danshen)
Conditions: Dyslipidemias;   Hypertension;   Vasodilation;   Oxidative Stress;   Inflammation
Interventions: Dietary Supplement: Salvia miltiorrhiza extract;   Dietary Supplement: Placebo
Outcome Measures: Hyperlipidemia;   Hypertension;   Endothelial function;   Plasma markers of oxidative stress;   Vascular inflammation and inflammatory activation of adipose tissue;   Hemostasis and hemorheological parameters;   Insulin sensitivity
10 Recruiting The Therapeutic Effects of Statins and Berberine on the Hyperlipemia
Condition: Dyslipidemias
Interventions: Drug: Berberine;Atorvastatin or Rosuvastatin;   Drug: Atorvastatin or Rosuvastatin
Outcome Measures: Change from baseline in combination statins with berberine on lipid level;   Adherence of statins and berberine treatment
11 Recruiting Dose-response Effect of Whey Protein Consumed as Pre-meal on Postprandial Lipaemia in Subjects With Metabolic Syndrome
Condition: Metabolic Syndrome
Intervention: Other: Whey protein
Outcome Measures: Dose-response of whey protein as pre-meal on triglycerides after a high-fat meal in subjects with the metabolic syndrome measured as incremental Area Under the Curve (iAUC -15 - 360 min);   Dose-response of whey protein as pre-meal on apolipoprotein B48 after a high-fat meal in subjects with the metabolic syndrome measured as incremental Area Under the Curve (iAUC -15 - 360 min);   Glucose responses measured as incremental Area Under the Curve (AUC -15 - 360 min);   Insulin responses measured as incremental Area Under the Curve (AUC -15 - 360 min);   Glucagon responses measured as incremental Area Under the Curve (AUC -15 - 360 min);   Glucagon-like peptide 1 (GLP-1) responses measured as incremental Area Under the Curve (AUC -15 - 360 min);   Gastric inhibitory peptide (GIP) responses measured as incremental Area Under the Curve (AUC -15 - 360 min)
12 Available Effect of Genes on Rosuvastatin Therapy for Hyperlipidemia
Condition: Hyperlipidemia
Interventions: Drug: rosuvastatin,fenofibrate;   Genetic: CYP2C9, UGT1A1, UGT1A3, OATP2, BCRP
Outcome Measure:
13 Recruiting Telemedicine Based Management of Hyperlipidemia
Condition: Hyperlipidemia
Intervention: Device: Self Monitoring Lipid Analyzer
Outcome Measure: Time to LDL goal
14 Not yet recruiting Efficacy Study of Metformin Glycinate on Postprandial Lipemia
Condition: Type 2 Diabetes
Interventions: Drug: Metformin glycinate;   Drug: Metformin Hydrochloride
Outcome Measures: Change in postprandial lipemia at 4 months;   Change in oxidized LDL at 4 months;   Change in FGF-21 levels at 4 months;   Change in A1C at 4 months;   Change in alanine aminotransferase at 4 months;   Change in uric acid at 4 months;   Number of Participants with Serious and Non-Serious Adverse Events
15 Unknown  Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia
Condition: Dyslipidemia
Interventions: Drug: High-dose rosuvastatin;   Drug: Statin plus fenofibrate;   Drug: Statin plus niacin ER/laropiprant
Outcome Measure: Changes in non-HDL-C levels
16 Recruiting Randomized Clinical Trial Of RN316 (PF-04950615) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Condition: Hyperlipidemia
Interventions: Drug: PF-04950615;   Other: Placebo
Outcome Measures: Percent Change from Baseline in LDL-C at Week 12;   Change from Baseline in Lipid Parameters at Week 12;   Change from Baseline in Lipid Parameters at Week 24;   Change from Baseline in Lipid Parameters at Week 52;   Proportion of Subjects Achieving Fasting LDL-C <= 100 mg/dL and <=70 mg/dL;   Plasma PF-04950615 concentration
17 Recruiting Randomized Clinical Trial of RN316 (PF-04950615) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events
Condition: Hyperlipidemia
Interventions: Drug: PF-04950615;   Other: Placebo
Outcome Measures: Percent Change from Baseline in LDL-C at Week 12;   Change from Baseline in Lipid Parameters at Week 12;   Change from Baseline in Lipid Parameters at Week 24;   Change from Baseline in Lipid Parameters at Week 52;   Proportion of Subjects Achieving Fasting LDL-C <= 100 mg/dL and <=70 mg/dL;   Plasma PF-04950615 concentration
18 Unknown  The Clinical Evaluation of Efficacy of Lipid-Lowing Tea on Hyperlipidemia Patients’ Lipid Profiles
Condition: Hyperlipidemia
Intervention: Drug: Lipid-lowing Tea
Outcome Measure:
19 Not yet recruiting Randomized Clinical Trial of RN316 (PF-04950615) in Subjects Who Are Intolerant to Statins
Condition: Hyperlipidemia
Interventions: Drug: PF-04950615;   Drug: Atorvastatin;   Other: Placebo for PF-04950615;   Other: Placebo for atorvastatin
Outcome Measures: Percentage change from baseline in fasting LDL-C at week 12;   Change from Baseline in Lipid Parameters at Week 12;   Change from Baseline in Lipid Parameters at Week 24;   Proportion of subjects achieving fasting LDL-C less or equal than 100mg/dL at week 12;   Proportion of subjects achieving fasting LDL-C less or equal than 100mg/dL at week 24;   Proportion of subjects achieving fasting LDL-C less or equal than 70mg/dL at week 12;   Proportion of subjects achieving fasting LDL-C less or equal than 70mg/dL at week 24;   Plasma PF-04950615 concentration at week 12;   Plasma PF-04950615 concentration at week 24;   Antidrug antibodies;   Proportion of subjects discontinuing treatment due to musculoskeletal adverse events
20 Recruiting to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia
Condition: HbA1c Level Associated With Lipid Compositions
Interventions: Drug: Pitavastatin calcium 4mg;   Drug: Pitavastatin calcium 2mg
Outcome Measures: The change of HbA1c before and after taking LIVALO®;   Incidence of diabetes;   Incidence of total cardiovascular (TVR-MACE) events;   The change of the lipid composition (T-chol, TG, LDL-C, HDL-C, ApoA1/ApoB);   The changes of hs-CRP, Adiponectin, blood glucose and Insulin levels